Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics


Madrigal Pharmaceuticals, Inc. (MDGL): $112.12

-2.23 (-1.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MDGL Stock Price Chart Interactive Chart >

Price chart for MDGL

MDGL Price/Volume Stats

Current price $112.12 52-week high $137.28
Prev. close $114.35 52-week low $56.82
Day low $112.04 Volume 98,921
Day high $115.39 Avg. volume 210,275
50-day MA $116.44 Dividend yield N/A
200-day MA $115.36 Market Cap 1.80B

Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.


MDGL Latest News Stream


Event/Time News Detail
Loading, please wait...

MDGL Latest Social Stream


Loading social stream, please wait...

View Full MDGL Social Stream

Latest MDGL News From Around the Web

Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com

B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | January 12, 2021

Is MDGL A Good Stock To Buy Now?

We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) based on that […]

Yahoo | December 17, 2020

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial

* Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday, November 13, 2020, at 4:30 PM ET. * In the 100 mg open label arm of MAESTRO-NAFLD: * At week 16, MRI-PDFF (magnetic resonance imaging-proton density fat fraction) reduction compared to baseline was 53% overall (p<0.0001) and up to 62% in key subgroups * At weeks 12-24, statistically significant lowering of liver enzymes, inflammatory biomarkers and atherogenic lipids and lipoproteins were observed * At week 16, compared to baseline, a meaningful reduction (p=0.003) in magnetic resonance elastography (MRE), a measure of liver of fibrosis and inflammation was seenCONSHOHOCKEN, P...

Yahoo | November 13, 2020

Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | November 12, 2020

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights - Stocks News Feed

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights. The original target enrollment for MAESTRO… Read More »Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

Stocks News Feed | November 5, 2020

Read More 'MDGL' Stories Here

MDGL Price Returns

1-mo -3.34%
3-mo -5.25%
6-mo 2.94%
1-year 28.39%
3-year -14.33%
5-year 1,181.37%
YTD 0.85%
2020 22.02%
2019 -19.17%
2018 22.80%
2017 516.04%
2016 21.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9383 seconds.